Trial Profile
Retrospective Analysis of Clinical Factors Associated With Greater Benefit of Axitinib in Metastatic Renal Cancer (AXILONG Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AXILONG
- Sponsors Pfizer
- 15 Feb 2020 Results of subgroup of patients (n=107) identifying clinical factors related to a high benefit of axitinib in mRCC, presented at the 2020 Genitourinary Cancers Symposium
- 01 May 2019 Status changed from active, no longer recruiting to completed.
- 22 Mar 2019 Status changed from recruiting to active, no longer recruiting.